AMP-activated protein kinase promotes human prostate cancer cell growth and survival

被引:159
作者
Park, Hyeon Ung [1 ]
Suy, Simeng [2 ]
Danner, Malika [3 ]
Dailey, Vernon [3 ]
Zhang, Ying [4 ]
Li, Henghong [5 ]
Hyduke, Daniel R. [5 ]
Collins, Brian T. [1 ]
Gagnon, Gregory [1 ]
Kallakury, Bhaskar [3 ]
Kumar, Deepak [6 ]
Brown, Milton L. [2 ]
Fornace, Albert [5 ]
Dritschilo, Anatoly [1 ]
Collins, Sean P. [1 ]
机构
[1] Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA
[2] Georgetown Univ, Med Ctr, Drug Discovery Program, Washington, DC 20007 USA
[3] Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA
[4] Georgetown Univ, Med Ctr, Biostat Unit, Washington, DC 20007 USA
[5] Georgetown Univ, Med Ctr, Dept Biochem & Mol & Cellular Biol, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
[6] Univ Dist Columbia, Dept Biol & Environm Sci, Washington, DC 20007 USA
基金
美国国家科学基金会;
关键词
ACETYL-COA CARBOXYLASE; CREB COACTIVATOR TORC2; TRANSCRIPTIONAL REGULATION; METABOLIC CHECKPOINT; INCREASED EXPRESSION; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; PHOSPHORYLATION; HYPOXIA; ENERGY;
D O I
10.1158/1535-7163.MCT-08-0631
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular mechanisms underlying the development and progression of prostate cancer are poorly understood. AMP-activated protein kinase (AMPK) is a serine-threonine kinase that is activated in response to the hypoxic conditions found in human prostate cancers. In response to energy depletion, AMPK activation promotes metabolic changes to maintain cell proliferation and survival. Here, we report prevalent activation of AMPK in human prostate cancers and provide evidence that inhibition or depletion of AMPK leads to decreased cell proliferation and increased cell death. AMPK was highly activated in 40% of human prostate cancer specimens examined. Endogenous AMPK was active in both the androgen-sensitive LNCaP cells and the androgen-independent CWR22Rv1 human prostate cancer cells. Depletion of AMPK catalytic subunits by small interfering RNA or inhibition of AMPK activity with a small-molecule AMPK inhibitor (compound C) suppresses human prostate cancer cell proliferation. Apoptotic cell death was induced in LNCaP and CWR22Rv1 cells at compound C concentrations that inhibited AMPK activity. The evidence provided here is the first report that the activated AMPK pathway is involved in the growth and survival of human prostate cancer and offers novel potential targets for chemoprevention of human prostate cancer. [Mol Cancer Ther 2009;8(4):733-41]
引用
收藏
页码:733 / 741
页数:9
相关论文
共 56 条
[11]   The regulation of energy generating metabolic pathways by p53 [J].
Corcoran, Chad A. ;
Huang, Ying ;
Sheikh, M. Saeed .
CANCER BIOLOGY & THERAPY, 2006, 5 (12) :1610-1613
[12]   5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE - A SPECIFIC METHOD FOR ACTIVATING AMP-ACTIVATED PROTEIN-KINASE IN INTACT-CELLS [J].
CORTON, JM ;
GILLESPIE, JG ;
HAWLEY, SA ;
HARDIE, DG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 229 (02) :558-565
[13]   Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer [J].
Cvetkovic, D ;
Movsas, B ;
Dicker, AP ;
Hanlon, AL ;
Greenberg, RE ;
Chapman, JD ;
Hanks, GE ;
Tricoli, JV .
UROLOGY, 2001, 57 (04) :821-825
[14]   Why do cancers have high aerobic glycolysis? [J].
Gatenby, RA ;
Gillies, RJ .
NATURE REVIEWS CANCER, 2004, 4 (11) :891-899
[15]   p53 and metabolism: Inside the TIGAR [J].
Green, Douglas R. ;
Chipuk, Jerry E. .
CELL, 2006, 126 (01) :30-32
[16]   AMPK phosphorylation of raptor mediates a metabolic checkpoint [J].
Gwinn, Dana M. ;
Shackelford, David B. ;
Egan, Daniel F. ;
Mihaylova, Maria M. ;
Mery, Annabelle ;
Vasquez, Debbie S. ;
Turk, Benjamin E. ;
Shaw, Reuben J. .
MOLECULAR CELL, 2008, 30 (02) :214-226
[17]  
HA J, 1994, J BIOL CHEM, V269, P22162
[18]   AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy [J].
Hardie, D. Grahame .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2007, 8 (10) :774-785
[19]   Ultra-high-throughput sequencing, microarray-based genomic selection and pharmacogenomics [J].
Hardiman, Gary .
PHARMACOGENOMICS, 2008, 9 (01) :5-9
[20]  
HAWLEY SA, CELL METAB, V52, P9